- Home
- HLVX vs ATHA Comparison
HLVX vs ATHA Comparison
Compare HLVX & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ATHA
- Stock Information
- Founded
- HLVX 2020
- ATHA 2011
- Country
- HLVX United States
- ATHA United States
- Employees
- HLVX N/A
- ATHA N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- HLVX Health Care
- ATHA Health Care
- Exchange
- HLVX Nasdaq
- ATHA Nasdaq
- Market Cap
- HLVX 87.6M
- ATHA 93.5M
- IPO Year
- HLVX 2022
- ATHA 2020
- Fundamental
- Price
- HLVX $1.89
- ATHA $0.72
- Analyst Decision
- HLVX Hold
- ATHA Buy
- Analyst Count
- HLVX 5
- ATHA 4
- Target Price
- HLVX $2.33
- ATHA $11.25
- AVG Volume (30 Days)
- HLVX 124.1K
- ATHA 14.2M
- Earning Date
- HLVX 11-07-2024
- ATHA 11-07-2024
- Dividend Yield
- HLVX N/A
- ATHA N/A
- EPS Growth
- HLVX N/A
- ATHA N/A
- EPS
- HLVX N/A
- ATHA N/A
- Revenue
- HLVX N/A
- ATHA N/A
- Revenue This Year
- HLVX N/A
- ATHA N/A
- Revenue Next Year
- HLVX N/A
- ATHA N/A
- P/E Ratio
- HLVX N/A
- ATHA N/A
- Revenue Growth
- HLVX N/A
- ATHA N/A
- 52 Week Low
- HLVX $1.55
- ATHA $0.41
- 52 Week High
- HLVX $20.22
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- HLVX 50.42
- ATHA 57.38
- Support Level
- HLVX $1.80
- ATHA $0.60
- Resistance Level
- HLVX $2.02
- ATHA $0.83
- Average True Range (ATR)
- HLVX 0.08
- ATHA 0.10
- MACD
- HLVX 0.01
- ATHA 0.04
- Stochastic Oscillator
- HLVX 41.86
- ATHA 80.59
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.